Psychedelic Resource List

 
 

GENERAL PSYCHEDELIC PAPERS

  • Johnson et al. Psychedelic medicine: a re-emerging therapeutic paradigm. CMAJ. v.187(14); 2015 Oct 6

  • Nicholas, D. Psychedelics. Pharmacol Rev. 2016 Apr; 68(2): 264–355

  • Carod-Artal, FJ. Hallucinogenic drugs in pre-Columbian Mesoamerican cultures. Neurologia. 2015 Jan-Feb;30(1):42-9

  • https://psychedelictimes.com/psychedelic-timeline/

  • Davis et al. Effects of Psilocybin-Assisted Therapy on Major Depressive Disorder A Randomized Clinical Trial. JAMA Psychiatry. 2021;78(5):481-489

  • Gukasyan et al. Efficacy and safety of psilocybin-assisted treatment for major depressive disorder: Prospective 12-month follow-up. Journal of Psychopharmacology 2022, Vol. 36(2) 151–158

  • Carhart-Harris RL et al. Trial of Psilocybin versus Escitalopram for Depression N Engl J Med 2021;384:1402-11.

  • Mitchell J et al. MDMA-assisted therapy for severe PTSD: a randomized, double-blind, placebo-controlled phase 3 study. Nature Medicine. VOL 27; JUNE 2021: 1025–1033.

  • Robin L Carhart-Harris & Guy M Goodwin . The Therapeutic Potential of Psychedelic Drugs: Past, Present, and Future Neuropsychopharmacology volume 42, pages 2105–2113 (2017)

  • Vendrell-Serres et al. Improvement of functional neurological disorder after administration of esketaminenasal spray: a case report. Ther Adv Psychopharmacol. 2021, Vol. 11: 1–6

  • Timmermann et al. Neural Correlates of the DMT Experience assessed with Multivariate EEG. Sci Rep. 2019 Nov 19;9(1):16324

KETAMINE

  • Berman et al. Antidepressant Effects of Ketamine in Depressed Patients. BIOL PSYCHIATRY 2000;47:351–354

EGO DISSOLUTION/EGO DEATH

  • Nour MM, Evans L, Nutt D, Carhart-Harris RL. Ego-Dissolution and Psychedelics: Validation of the Ego-Dissolution Inventory (EDI). Front Hum Neurosci. 2016 Jun 14;10:269

  • Lebedev AV, Lövdén M, Rosenthal G, Feilding A, Nutt DJ, Carhart-Harris RL. Finding the self by losing the self: Neural correlates of ego-dissolution under psilocybin. Hum Brain Mapp. 2015 Aug;36(8):3137-53

  • Mason NL, Kuypers KPC, Müller F, Reckweg J, Tse DHY, Toennes SW, Hutten NRPW, Jansen JFA, Stiers P, Feilding A, Ramaekers JG. Me, myself, bye: regional alterations in glutamate and the experience of ego dissolution with psilocybin. Neuropsychopharmacology. 2020 Nov;45(12):2003-2011

  • Ko K, Knight G, Rucker JJ, Cleare AJ. Psychedelics, Mystical Experience, and Therapeutic Efficacy: A Systematic Review. Front Psychiatry. 2022 Jul 12;13:917199

  • Madsen MK, Stenbæk DS, Arvidsson A, Armand S, Marstrand-Joergensen MR, Johansen SS, Linnet K, Ozenne B, Knudsen GM, Fisher PM. Psilocybin-induced changes in brain network integrity and segregation correlate with plasma psilocin level and psychedelic experience. Eur Neuropsychopharmacol. 2021 Sep;50:121-132

  • Letheby C, Gerrans P. Self unbound: ego dissolution in psychedelic experience. Neurosci Conscious. 2017 Jun 30;2017(1)

  • Stoliker D, Egan GF, Friston KJ, Razi A. Neural Mechanisms and Psychology of Psychedelic Ego Dissolution. Pharmacol Rev. 2022 Oct;74(4):876-917

  • Carhart-Harris RL, Muthukumaraswamy S, Roseman L, Kaelen M, Droog W, Murphy K, Tagliazucchi E, Schenberg EE, Nest T, Orban C, Leech R, Williams LT, Williams TM, Bolstridge M, Sessa B, McGonigle J, Sereno MI, Nichols D, Hellyer PJ, Hobden P, Evans J, Singh KD, Wise RG, Curran HV, Feilding A, Nutt DJ. Neural correlates of the LSD experience revealed by multimodal neuroimaging. Proc Natl Acad Sci U S A. 2016 Apr 26;113(17):4853-8

  • Carhart-Harris RL, Leech R, Erritzoe D, Williams TM, Stone JM, Evans J, Sharp DJ, Feilding A, Wise RG, Nutt DJ. Functional connectivity measures after psilocybin inform a novel hypothesis of early psychosis. Schizophr Bull. 2013 Nov;39(6):1343-51

  • Muthukumaraswamy SD, Carhart-Harris RL, Moran RJ, Brookes MJ, Williams TM, Errtizoe D, Sessa B, Papadopoulos A, Bolstridge M, Singh KD, Feilding A, Friston KJ, Nutt DJ. Broadband cortical desynchronization underlies the human psychedelic state. J Neurosci. 2013 Sep 18;33(38):15171-83

  • Tagliazucchi E, Roseman L, Kaelen M, Orban C, Muthukumaraswamy SD, Murphy K, Laufs H, Leech R, McGonigle J, Crossley N, Bullmore E, Williams T, Bolstridge M, Feilding A, Nutt DJ, Carhart-Harris R. Increased Global Functional Connectivity Correlates with LSD-Induced Ego Dissolution. Curr Biol. 2016 Apr 25;26(8):1043-50

  • Lebedev AV, Kaelen M, Lövdén M, Nilsson J, Feilding A, Nutt DJ, Carhart-Harris RL. LSD-induced entropic brain activity predicts subsequent personality change. Hum Brain Mapp. 2016 Sep;37(9):3203-13. doi: 10.1002/hbm.23234. Epub 2016 May 6

  • Millière R, Carhart-Harris RL, Roseman L, Trautwein FM, Berkovich-Ohana A. Psychedelics, Meditation, and Self-Consciousness. Front Psychol. 2018 Sep 4;9:1475

  • Millière R. Looking for the Self: Phenomenology, Neurophysiology and Philosophical Significance of Drug-induced Ego Dissolution. Front Hum Neurosci. 2017 May 23;11:245

  • Glowacki DR, Williams RR, Wonnacott MD, Maynard OM, Freire R, Pike JE, Chatziapostolou M. Group VR experiences can produce ego attenuation and connectedness comparable to psychedelics. Sci Rep. 2022 May 30;12(1):8995.

  • Griffiths R, Richards W, Johnson M, McCann U, Jesse R. Mystical-type experiences occasioned by psilocybin mediate the attribution of personal meaning and spiritual significance 14 months later. J Psychopharmacol. 2008 Aug;22(6):621-32.

  • Griffiths RR, Johnson MW, Richards WA, Richards BD, McCann U, & Jesse R (2011). Psilocybin occasioned mystical-type experiences: immediate and persisting dose-related effects. Psychopharmacology (Berl), 218(4), 649–665.

  • Barrett FS, Griffiths RR. Classic Hallucinogens and Mystical Experiences: Phenomenology and Neural Correlates. Curr Top Behav Neurosci. 2018;36:393-430

  • Barrett FS, Johnson MW, Griffiths RR. Validation of the revised Mystical Experience Questionnaire in experimental sessions with psilocybin. J Psychopharmacol. 2015 Nov;29(11):1182-90.

  • Stace WT. Mysticism and Philosophy. New York: MacMillan Press. 1960

  • Nour MM, Carhart-Harris RL. Psychedelics and the science of self-experience. Br J Psychiatry. 2017 Mar;210(3):177-179.

  • Blanke O, Mohr C, Michel CM, Pascual-Leone A, Brugger P, Seeck M, Landis T, Thut G. Linking out-of-body experience and self processing to mental own-body imagery at the temporoparietal junction. J Neurosci. 2005 Jan 19;25(3):550-7

  • Blanke O, Arzy S. The out-of-body experience: disturbed self-processing at the temporo-parietal junction. Neuroscientist. 2005 Feb;11(1):16-24

MYSTICAL EXPERIENCE & THERAPEUTIC BENEFIT

  • Garcia-Romeu A, Griffiths RR, Johnson MW. Psilocybin-occasioned mystical experiences in the treatment of tobacco addiction. Curr Drug Abuse Rev. 2014;7(3):157-64.

  • Griffiths RR, Johnson MW, Carducci MA, Umbricht A, Richards WA, Richards BD, Cosimano MP, Klinedinst MA. Psilocybin produces substantial and sustained decreases in depression and anxiety in patients with life-threatening cancer: A randomized double-blind trial. J Psychopharmacol. 2016 Dec;30(12):1181-1197.

  • Ross S, Bossis A, Guss J, Agin-Liebes G, Malone T, Cohen B, Mennenga SE, Belser A, Kalliontzi K, Babb J, Su Z, Corby P, Schmidt BL. Rapid and sustained symptom reduction following psilocybin treatment for anxiety and depression in patients with life-threatening cancer: a randomized controlled trial. J Psychopharmacol. 2016 Dec;30(12):1165-1180.

  • Bogenschutz MP, Forcehimes AA, Pommy JA, Wilcox CE, Barbosa PC, Strassman RJ. Psilocybin-assisted treatment for alcohol dependence: a proof-of-concept study. J Psychopharmacol. 2015 Mar;29(3):289-99.

  • William A. Richards, John C. Rhead, Francesco B. Dileo, Richard Yensen & Albert A. Kurland (1977) The Peak Experience Variable in DPT-Assisted Psychotherapy with Cancer Patients, Journal of Psychedelic Drugs, 9:1, 1-10

HEADACHE

  • Schindler, E.A., Psychedelics as preventive treatment in headache and chronic pain disorders. Neuropharmacology 215 (2022) 109166

  • Sewell et al. Response of cluster headache to psilocybin and LSD. Neurology. June 27, 2006; 66 (12)

  • Schindler et al. Exploratory Controlled Study of the Migraine-Suppressing Effects of Psilocybin. Neurotherapeutics (2021) 18:534–543

  • Matharu, M.S., van Vliet, J.A., Ferrari, M.D., Goadsby, P.J., 2005. Verapamil induced gingival enlargement in cluster headache. J. Neurol. Neurosurg. Psychiatry 76, 124–127.

  • Karst, M., Halpern, J.H., Bernateck, M., Passie, T., 2010. The non-hallucinogen 2-bromolysergic acid diethylamide as preventative treatment for cluster headache: an open, non-randomized case series. Cephalalgia 30, 1140–1144.

  • Post, M.D., 2014. Treatment of Cluster Headache Symptoms Using Synthetic Tryptamine N,N-diallyl-5 Methoxytryptamine.

  • Johnson, S., Black, Q.C., 2020. Can psychedelics alleviate symptoms of cluster headache and accompanying mental health problems? A case report involving Hawaiian baby woodrose. J. Psychoact. Drugs 1–5.

  • Sewell RA, Halpern JH, Pope HG, Jr. Response of cluster headache to psilocybin and LSD. Neurology. 2006;66(12):1920-1922.

  • Di Lorenzo, C., Coppola, G., Di Lorenzo, G., Bracaglia, M., Rossi, P., Pierelli, F., 2016. The use of illicit drugs as self-medication in the treatment of cluster headache: results from an Italian online survey. Cephalalgia 36, 194–198.

  • Schindler, E.A., Gottschalk, C.H., Weil, M.J., Shapiro, R.E., Wright, D.A., Sewell, R.A., 2015. Indoleamine hallucinogens in cluster headache: results of the Clusterbusters medication use survey. J. Psychoact. Drugs 47, 372–381.

  • Sicuteri, F., 1963. Prophylactic Treatment of Migraine by Means of Lysergic Acid Derivatives, pp. 116–125. Triangle 6.

PEDIATRICS

  • Dwyer et al. Efficacy of Intravenous Ketamine in Adolescent Treatment-Resistant Depression: A Randomized Midazolam-Controlled. TrialAmJPsychiatry 2021; 178:352–362